Literature DB >> 1912582

Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.

J K Hitzler1, H Martinez-Valdez, D B Bergsagel, M D Minden, H A Messner.   

Abstract

Interleukin-6 (IL-6) has been shown to stimulate the proliferation of multiple myeloma cells purified to a high degree from human bone marrow. IL-6 production in multiple myeloma has been attributed to cells belonging to the myeloma clone, thus supporting a mechanism of autostimulation. In addition, it has been shown that IL-6 may be produced by auxiliary cell populations of the bone marrow that are not part of the myeloma clone. A definitive separation of both putative sources for IL-6 may be difficult to achieve in fresh patient IL-6 growth requirement and production by pure myeloma cell populations using seven human myeloma cell lines (OCI-My 1 to 7) that were established from patients with advanced disease. The proliferative response of each line to recombinant IL-6 was measured in a clonogenic assay providing human plasma and methylcellulose as a viscous support and by 3H-thymidine uptake in liquid suspension culture. We observed marked heterogeneity, ranging from IL-6-dependent colony formation by OCI-My 4, to IL-6-independent growth. All lines expressed mRNA for the IL-6 receptor. Expression of IL-6 mRNA was analyzed after amplification by polymerase chain reaction and was present in five of seven lines. IL-6 protein was detected by enzyme-linked immunosorbent assay (ELISA) in the culture supernatants of two lines (OCI-My 3 and 2). Its functional activity was confirmed in a bioassay using the IL-6-dependent murine hybridoma line B 13.29. This activity was neutralized by anti-IL-6 antibody. Two lines did not express mRNA for IL-6. The remaining three lines expressed mRNA for IL-6, but did not secrete IL-6 protein. Immunoprecipitation experiments with lysates of one of these three lines did not detect the presence of IL-6 protein. These results suggest that autocrine stimulation by IL-6 may occur in some cell lines derived from patients with multiple myeloma. However, it does not represent a universal mechanism in myeloma cell growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912582

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

Authors:  Shuhong Zhang; Attaya Suvannasankha; Colin D Crean; Valerie L White; Ching-Shih Chen; Sherif S Farag
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Authors:  P L Bergsagel; M Chesi; E Nardini; L A Brents; S L Kirby; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

4.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

5.  Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.

Authors:  D D Biggs; P Kraj; J Goldman; L Jefferies; C Carchidi; K Anderson; L E Silberstein
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

6.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 7.  Thalidomide-a notorious sedative to a wonder anticancer drug.

Authors:  Shuang Zhou; Fengfei Wang; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Authors:  D Chiron; S Maïga; S Surget; G Descamps; P Gomez-Bougie; S Traore; N Robillard; P Moreau; S Le Gouill; R Bataille; M Amiot; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-06-07       Impact factor: 11.037

9.  Interleukin 6 is essential for in vivo development of B lineage neoplasms.

Authors:  D M Hilbert; M Kopf; B A Mock; G Köhler; S Rudikoff
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

10.  Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.

Authors:  Quanyi Lu; Xianghua Lin; Jean Feng; Xiangmin Zhao; Ruth Gallagher; Marietta Y Lee; Jen-Wei Chiao; Delong Liu
Journal:  J Hematol Oncol       Date:  2008-06-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.